Phase 2 N=28 Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Acute Myeloid Leukemia
Primary: Response Rate of Crenolanib Besylate Combination Therapy — 2; 0; 3; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=29 Motivational Strategies To Empower African Americans To Improve Dialysis Adherence
End Stage Renal Disease on Dialysis
Primary: Dialysis Treatment Adherence — 95.85; 93.26 percentage of minutes completed — p=0.101
Phase 3 N=307 A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa
Parkinson Disease
Primary: Change From Baseline to Week 16 in the Mean Total Daily "OFF" Time — -1.93; -0.88 Hours — p=<.0001
Phase 4 N=77 Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
Coronary Artery Disease · Acute Coronary Syndrome
Primary: Platelet Reactivity Measured by VerifyNow — 23; 153; 65 PRU
Phase 3 N=1,673 Efficacy and Safety of IVM/ALB Co-administration
Trichuriasis
Primary: Number of Participants T. Trichiura Egg Negative Post-Treatment (Cured) — 24; 32; 16; 140 Participants
N/A N=360 Urgent Care Management of Respiratory Illness Enabled With Novel Testing Pathway
Viral Infection · Acute Respiratory Infection · Upper Resp Tract Infection
Primary: Satisfaction With Time to Receive Result — 180; 53; 3; 72 participants
Phase 2 N=86 A Study of TAS-120 in Patients With Advanced Solid Tumors
Cholangiocarcinoma · Urothelial Cancer · Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors
Primary: Phase 1: Dose Escalation-Maximum Tolerated Dose (MTD) — NA; 20 Milligrams
Phase 3 N=1,499 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Kidney Cancer
Primary: 5-year Recurrence-free Survival (RFS) — 63; 67 percentage of paticipants
N/A N=285 Evaluation of the Wits Workout Wellness Program for Older Adults
Cognitive Decline · Social Isolation · Health Behaviors
Primary: Change in Cognitive Function — 0.28; .65; 1.84; -.73 T score
Phase 2 N=373 Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Carcinoma, Non-Small-Cell Lung
Primary: Overall Response Rate (ORR) by Blinded Independent Review Committee (BIRC) Assessment — 29.0; 11.9; 9.3; 6.7 Percentage of Participants
Phase 4 N=22 EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)
Lipid Disorder
Primary: Low-density Lipoprotein Cholesterol (LDL-C) Levels at Baseline and Day 30 — 110; 84.0 mg/dL
N/A N=38 Quantifying the Venous Congestion Curve of a Tissue Oximetry Device
Post-Op Complication · Skin Flap Necrosis
Primary: Transcutaneous Oximetry (StO2) of Vascular Occlusion Test at 0.5 Hours — 70.353 percentage of oxygen saturation
N/A N=21 Low Intensity Focused Ultrasound for Learning and Memory and Emotion Regulation
Brain Diseases · Memory Disorders · Learning Disabilities
Primary: Rey Auditory Verbal Learning Task — 50.00; 50.29; 47.59; 47.88 Words Recalled
Phase 2 N=36 Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation
Loss of Chromosome 17p · Recurrent Chronic Lymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma
Primary: Number of Participants With a Response for Cohorts 1 and 3 — 5; 10 Participants
Phase 4 N=209 Dexamethasone for Migraine - Dose Comparison
Migraine
Primary: Number of Subjects With Headaches Who Have Sustained Headache Relief for 48 Hours — 35; 42 Participants